Novo Nordisk A/s Class B · OMXCOP:NOVO_B
Novo Nordisk A/s Class B — Technical Presentation (March 2026)
18 slides from Novo Nordisk A/s Class B's technical presentation, Mar 18, 2026
Slide 1: Efficacy and safety of oral semaglutide 14 mg in early-stage symptomatic Alzheimer's disease
1 Novo Nordisk® Efficacy and safety of oral semaglutide 14 mg (flexible dose) in early-stage symptomatic Alzheimer’s disease: results from the phase 3 evoke and evoke+ randomised placebo-controlled trials Click here to view the published article Cummings JL et al. Lancet 2026; doi: 10.1016/S0140-673
Slide 2: Contents
2 Novo Nordisk® Publication highlights Introduction evoke and evoke+ trial designs Participant distribution Contents Demographic and baseline characteristics Clinical efficacy results CSF biomarker results Safety results Conclusions
Slide 3: Publication highlights
3 Novo Nordisk® 01 Oral semaglutide was not efficacious in slowing clinical progression in participants with early AD Publication 02 Significant changes were observed in CSF biomarkers, but these did not translate into clinical efficacy highlights Safety of oral semaglutide in early AD was consisten
Slide 4: Introduction
4 Novo Nordisk® • Semaglutide, a GLP-1 receptor agonist, is approved for the treatment of T2D, weight management and cardiovascular risk reduction in those with established cardiovascular disease and overweight or obesity1–4 • Studies in murine models have demonstrated GLP-1 receptor agonists impact
Slide 5: evoke and evoke+ trial designs
5 Novo Nordisk® evoke and evoke+ trial designs Key inclusion criteria1 Trial designs1 • Age 55–85 years old (inclusive) • Multicentre, randomised, double-blind, placebo-controlled phase 3 trials at • MCI or mild dementia due to AD (according to NIA-AA 2018 criteria) 566 sites in 40 countries with FP
Slide 6: evoke and evoke+ endpoints
6 Novo Nordisk® evoke and evoke+ Primary endpoint Confirmatory secondary Supportive secondary endpoints endpoints† Changes from baseline to week 104 (in each trial) Change in CDR-SB Change in ADCS-ADL-MCI ADAS-Cog-13 score MoCA score ADCOMS MMSE score score from baseline to score from baseline to we
Slide 7: evoke and evoke+ participant distribution
7 Novo Nordisk® evoke and evoke+ participant distribution evoke: screened (N=4825) evoke: screened (N=5156) evoke: randomised (N=1855) evoke+: randomised (N=1953) Oral semaglutide (n=928; 100%) Placebo (n=927; 100%) Oral semaglutide (n=976; 100%) Placebo (n=977; 100%) Exposed (n=924; 99.6%) Exposed
Slide 8: Key demographics and baseline characteristics
8 Novo Nordisk® Key demographics and baseline characteristics1,2 evoke evoke+ Pooled Oral semaglutide Placebo Oral semaglutide Placebo Total Male, % 47.3 46.5 47.2 49.0 47.5 Female, % 52.7 53.5 52.8 51.0 52.5 Age, mean (SD) 71.9 (7.0) years 71.7 (7.1) years 72.6 (7.0) years 72.5 (7.2) years 72.2 (7.
Slide 9: Key demographics and baseline characteristics
9 Novo Nordisk® Key demographics and baseline characteristics1,2 evoke evoke+ Pooled Oral semaglutide Placebo Oral semaglutide Placebo Total <18.5 kg/m2, % 3.0 1.9 2.3 2.9 2.5 18.5 to <25 kg/m2, % 45.4 46.6 47.4 47.6 46.8 25 to <30 kg/m2, % 36.3 35.9 34.2 33.7 35.0 ≥30 kg/m2, % 15.3 15.0 16.0 15.8 1
Slide 10: Oral semaglutide was not efficacious in slowing clinical progression in participants with early AD
10 Novo Nordisk® Oral semaglutide was not efficacious in slowing clinical progression in participants with early AD
Slide 11: Change in CDR-SB score from baseline to week 104
11 Novo Nordisk® Oral semaglutide did not slow cognitive and functional decline in participants with early AD versus placebo in either trial Hybrid-HTC estimand Change in CDR-SB score from baseline to week 104 evoke evoke+ Mean (SD) CDR-SB score at baseline: 3.7 (1.5) Mean (SD) CDR-SB score at basel
Slide 12: Change in ADCS-ADL-MCI score from baseline to week 104
12 Novo Nordisk® Oral semaglutide did not slow functional decline in participants with early AD versus placebo in either trial Hybrid-HTC estimand Change in ADCS-ADL-MCI score from baseline to week 104 evoke evoke+ Mean (SD) ADCS-ADL-MCI score at baseline: 39.4 (7.3) Mean (SD) ADCS-ADL-MCI score at
Slide 13: Time to progression to CDR global score ≥1.0
13 Novo Nordisk® Oral semaglutide did not delay time to progression to dementia in participants with MCI across both trials Hybrid-HTC estimand Time to progression to CDR global score ≥1.0 among participants with baseline CDR global score 0.5, pooled evoke(+) Pooled 100 Cumulative incidence (%) 75 5
Slide 14: Significant changes were observed in CSF biomarkers, but did not translate into clinical efficacy
14 Novo Nordisk® Significant changes were observed in CSF biomarkers, but these did not translate into clinical efficacy
Slide 15: CSF biomarker results: AD, neurodegeneration, complement system
15 Novo Nordisk® Unadjusted ETR 95% CI p value pTau181 (Elecsys) 0.92 0.87, 0.97 0.0035 evoke(+) CSF substudy npTau205 (C2N) 0.91 0.83, 0.99 0.026 pTau217 (C2N) 0.90 0.81, 0.99 0.038 n=199 npTau181 (C2N) 0.91 0.84, 1.00 0.043 pTau217/npTau217 (ratio; C2N) 0.96 0.91, 1.01 0.085 AD biomarkers† npTau21
Slide 16: Safety of oral semaglutide in early AD was consistent with the known safety profile
16 Novo Nordisk® Safety of oral semaglutide in early AD was consistent with the known safety profile of semaglutide
Slide 17: Adverse events, pooled
17 Novo Nordisk® Pooled Any AE SAE AEs leading to permanent trial product discontinuation † Fatal events Weight decreased Decreased appetite Nausea AEs occurring in ≥10% of participants Diarrhoea Vomiting COVID-19 0 10 20 30 40 50 60 70 80 90 100 Proportion of participants (%) Oral semaglutide Cummi
Slide 18: Conclusions
18 Novo Nordisk® • Once-daily oral semaglutide 14 mg did not slow cognitive and functional decline versus placebo at 104 weeks in participants with MCI or mild dementia due to AD • Several AD-relevant CSF biomarkers were significantly reduced with semaglutide, but these effects did not Conclusions t